| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CCL26 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CCL26抗体的3篇文献示例(注：以下为虚构示例，实际文献需通过学术数据库查询)：
1. **《CCL26介导嗜酸性粒细胞募集在过敏性哮喘中的作用》**
作者：Smith A, et al.
摘要：研究通过抗CCL26抗体阻断实验，证明CCL26在哮喘模型中驱动嗜酸性粒细胞向肺组织浸润，提示其作为治疗靶点的潜力。
2. **《肿瘤微环境中CCL26表达与巨噬细胞极化的关联》**
作者：Zhang Y, et al.
摘要：利用CCL26特异性抗体检测发现，CCL26在肝癌微环境中高表达，并通过调控巨噬细胞M2型极化促进肿瘤进展。
3. **《中和抗体抑制CCL26缓解特应性皮炎的实验研究》**
作者：Tanaka K, et al.
摘要：开发了一种人源化抗CCL26单克隆抗体，在动物模型中显著减轻皮肤炎症反应，证实其治疗特应性皮炎的有效性。
如需真实文献，建议在PubMed或Web of Science中检索关键词“CCL26 antibody”或“anti-CCL26”。
CCL26. also known as eotaxin-3. is a chemokine belonging to the CC subfamily that plays a critical role in recruiting immune cells, particularly eosinophils, via interaction with its receptor CCR3. It is primarily involved in inflammatory and allergic responses, contributing to conditions like asthma, atopic dermatitis, and eosinophilic disorders. CCL26 is structurally similar to other eotaxin family members (CCL11. CCL24) but is distinguished by its unique expression patterns and regulatory mechanisms. It is produced by epithelial cells, endothelial cells, and fibroblasts, often induced by pro-inflammatory cytokines such as IL-4 and IL-13.
CCL26 antibodies are immunological tools designed to detect, quantify, or neutralize CCL26 in experimental or therapeutic contexts. In research, these antibodies are widely used in techniques like ELISA, Western blotting, and immunohistochemistry to study CCL26’s role in disease pathogenesis or immune cell migration. Therapeutically, anti-CCL26 antibodies have been explored as potential agents to block CCR3-mediated signaling, thereby attenuating eosinophil infiltration and inflammation in allergic diseases.
Recent studies highlight CCL26's emerging roles in cancer and fibrosis, broadening the scope of its antibody applications. However, challenges remain in ensuring antibody specificity and minimizing off-target effects. Continued development of monoclonal antibodies with high affinity and neutralization efficiency may offer novel strategies for targeting CCL26 in complex inflammatory diseases.
×
